Suppr超能文献

分子类型和最大转移直径影响前哨淋巴结活检阳性的乳腺癌患者腋窝复发风险。

Molecular type and maximal metastasis diameter influence risk of axillary recurrence in breast cancer patients after positive sentinel lymph node biopsy.

作者信息

Falco Michał, Masojć Bartłomiej, Kram Andrzej

机构信息

Radiation Oncology Department, West Pomeranian Oncology Center, Szczecin, Poland.

Pathology Department, West Pomeranian Oncology Center, Szczecin, Poland.

出版信息

Rep Pract Oncol Radiother. 2021 Sep 30;26(5):785-792. doi: 10.5603/RPOR.a2021.0101. eCollection 2021.

Abstract

BACKGROUND

Breast cancer patients with positive sentinel lymph node biopsy (SLNB) may be spared axillary lymph node dissection (ALND) in favour of irradiation. The aim of the study was to estimate local control probability in the axilla (axLCP).

MATERIALS AND METHODS

We identified 1832 invasive breast cancer patients who had undergone SLNB at our centre. We measured maximal metastasis diameter (SLDmax) in the sentinel lymph nodes and lymph node metastasis volume (VALN) from ALND in 246 patients with one or two positive SLNs. We calculated axLCP after irradiation and systemic treatment for different molecular types.

RESULTS

VALN values are higher for high grade tumours and larger metastases in SLNs (> 5 mm). It is smaller in luminal A tumours. axLCP is high, nearly 100%, in all molecular types in radiation sensitive tumours (SF2 Gy = 0.45), except luminal B. Expected axLCP is relatively low (67%) in luminal B radiation sensitive tumours with no chemotherapy and nearly 100% with chemotherapy.

CONCLUSION

VALN values differ among molecular tumour types. They depend on SLNDmax and tumour grade. New prognostic factors are needed for selected luminal B breast cancer patients (i.e. high grade tumours, large metastases in SLNs) after positive SLNB intended to be spared ALND and chemotherapy.

摘要

背景

前哨淋巴结活检(SLNB)结果为阳性的乳腺癌患者,可能无需进行腋窝淋巴结清扫(ALND),而采用放射治疗。本研究的目的是评估腋窝局部控制概率(axLCP)。

材料与方法

我们确定了1832例在本中心接受过SLNB的浸润性乳腺癌患者。我们测量了246例有一个或两个前哨淋巴结阳性患者的前哨淋巴结最大转移直径(SLDmax)和腋窝淋巴结清扫术中的淋巴结转移体积(VALN)。我们计算了不同分子类型在放疗和全身治疗后的axLCP。

结果

高级别肿瘤以及前哨淋巴结中转移灶较大(>5mm)的患者VALN值较高。管腔A型肿瘤的VALN值较小。除管腔B型外,放射敏感肿瘤(SF2Gy = 0.45)的所有分子类型的axLCP都很高,接近100%。在未进行化疗的管腔B型放射敏感肿瘤中,预期axLCP相对较低(67%),而进行化疗时则接近100%。

结论

VALN值在不同分子肿瘤类型之间存在差异。它们取决于SLNDmax和肿瘤分级。对于前哨淋巴结活检阳性且打算避免进行ALND和化疗的特定管腔B型乳腺癌患者(即高级别肿瘤、前哨淋巴结中有大转移灶),需要新的预后因素。

相似文献

本文引用的文献

4
Development and Validation of a Novel Radiosensitivity Signature in Human Breast Cancer.新型乳腺癌放射敏感性标志物的建立与验证
Clin Cancer Res. 2015 Aug 15;21(16):3667-77. doi: 10.1158/1078-0432.CCR-14-2898. Epub 2015 Apr 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验